Prices delayed ≤15 min
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyv
Frequently Asked Questions about LLY
What does Eli Lilly and Company (LLY) do?
Eli Lilly and Company is a global leader in the healthcare sector, focusing on the discovery, development, and marketing of human pharmaceuticals. The company offers a diverse range of products, including insulin therapies such as Basaglar and Humalog, which are crucial for diabetes management.
Is LLY stock a good investment in 2026?
While specific valuation metrics like P/E ratio and revenue growth are currently unavailable, Eli Lilly's strong position in the healthcare industry suggests potential for growth. Investors should consider industry trends and the company's innovative pipeline to make informed decisions.
What is Eli Lilly and Company's market capitalisation and stock price?
As of now, Eli Lilly's market capitalisation and stock price are not available. However, investors typically look at these metrics in conjunction with the 52-week high and low to gauge performance.
Does LLY pay dividends to shareholders?
Eli Lilly does not currently pay dividends to its shareholders. Instead, the company appears to reinvest its earnings into research and development to fuel future growth.
How profitable is Eli Lilly and Company?
Eli Lilly's profitability metrics, such as net income and return on equity (ROE), are currently not disclosed. However, the company's operations in the pharmaceutical sector typically aim for strong margins and cash flow.
What is LLY's P/E ratio and is the stock overvalued?
The P/E ratio for Eli Lilly is not available at this time, making it difficult to assess valuation directly. Comparatively, the healthcare sector often has varying P/E ratios, so analysts may need to consider other factors.
How much debt does Eli Lilly and Company have?
Currently, Eli Lilly's debt/equity ratio is not provided, which limits insight into its balance sheet health. However, a low beta of 0.37 suggests that the company may have a stable financial position.
What is LLY's 52-week trading range?
At this moment, the 52-week trading range for Eli Lilly is not available. Investors usually analyze this range along with moving averages to understand stock volatility and price trends.
Is LLY a growth stock or value stock?
Specific revenue growth and EPS growth figures for Eli Lilly are currently unavailable, making it challenging to categorize the stock definitively. However, the company’s focus on innovative pharmaceuticals often aligns it more closely with growth stock characteristics.
What are the main risks of investing in LLY?
Investing in Eli Lilly carries specific risks, including a low beta of 0.37, indicating less volatility, but also potential competitive pressures in the pharmaceutical sector. Additionally, the lack of available financial metrics may pose risks regarding the company's market position and future growth.